[go: up one dir, main page]

EP1303497A1 - Amidoalkyle-uraciles substitues utilises comme inhibiteurs de parp (poly(adp-ribose)-polymerase) - Google Patents

Amidoalkyle-uraciles substitues utilises comme inhibiteurs de parp (poly(adp-ribose)-polymerase)

Info

Publication number
EP1303497A1
EP1303497A1 EP01947443A EP01947443A EP1303497A1 EP 1303497 A1 EP1303497 A1 EP 1303497A1 EP 01947443 A EP01947443 A EP 01947443A EP 01947443 A EP01947443 A EP 01947443A EP 1303497 A1 EP1303497 A1 EP 1303497A1
Authority
EP
European Patent Office
Prior art keywords
substituted
alkyl
optionally
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01947443A
Other languages
German (de)
English (en)
Inventor
Michael Härter
Barbara Albrecht
Michael Gerisch
Gabriele HANDKE-ERGÜDEN
Joachim Hütter
Axel Jensen
Thomas Krahn
Joachim Mittendorf
Felix Oehme
Karl-Heinz Schlemmer
Henning Steinhagen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Healthcare AG filed Critical Bayer AG
Publication of EP1303497A1 publication Critical patent/EP1303497A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to new chemical compounds, a process for their preparation and their use as medicaments, in particular for the prevention and / or therapy of ischemia and reperfusion damage.
  • NMDA N-methyl-D-aspartate
  • NO-induced neurotoxicity Zhang et al., Science, 263, 687-689 (1994); Wallis et al., NeuroReport, 5, 245-248 (1993)]
  • cerebral ischemia Endres et al., J. Cereb. Blood Flow Metabol., 17, 1143-1151 (1997)]
  • traumatic brain injuries Wallis et al., Brain Res., 710, 169-177 (1996)] and ischemia / -
  • PARS knock-out mice that are healthy and capable of reproduction are essentially protected against reperfusion damage.
  • the infiltration of neutrophils is reduced by 50% and the structure of the myocardial tissue is preserved during the reperfusion phase.
  • Small-molecule PARS inhibitors such as 3-aminobenzamide or 1,5-dihydroxyisoquinoline protect the tissue against necrotic cell death (reduction of the infarct size by 30 to 48%) and delay the myocardial damage in the case of ischemia or reperfusion damage in the heart and brain and neuronal dysfunction.
  • 3-aminobenzamide is a non-specific PARS inhibitor which also inhibits cytochrome P 450 (Eriksson et al., Toxicology and applied Pharmacology, 136, 324-331 (1996)); 5-Iodo-6-amino-1,2-benzopyrone, on the other hand, shows strong side effects (Szabo and Dawson, Trends in Pharmacol. Sciences, 19, 287-298 (1998)).
  • most inhibitors are not very potent and therefore only show an effect in animals at a relatively high dosage (Thiemermann et al., Proc. Natl. Acad. Sei., 94, 679-683 (1997)).
  • JP-A-03264579 and Chem. Pharm. Bull. 38 (10), 2726-2732 (1990) describe bicyclic 2,4- (1H, 3H) -pyrimidinediones as 5-HT 2 antagonists for the treatment of cardiovascular diseases, depression and other mental illnesses.
  • US Pat. No. 5,859,014 discloses tetrahydroquinazolinedione derivatives as evadrenergic receptor antagonists for the treatment of prostate hypertrophy.
  • WO-A-00/42025 describes dihydropyrimidinones as PARS inhibitors.
  • DE-A-1959705 and DE-A-2126148 list uracil derivatives for the production of crop protection agents.
  • DE-A-2142317 names uracil derivatives with hypnotic properties.
  • various bridged uracils are described in the literature as nucleoside analogues with potential antiviral activity (e.g.
  • the object of the present invention is now to provide new substances for the prevention and / or therapy of complications, in particular of
  • the compounds according to the invention presumably act as inhibitors of poly (ADP-ribose) synthetase (PARS).
  • PARS poly (ADP-ribose) synthetase
  • R 1 represents hydrogen, (-C ⁇ alkyl which is optionally mono- or polysubstituted by halogen, or (C 3 -C 8 ) cycloalkyl,
  • Diastereomers as well as their respective mixtures. Like the diastereomers, the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner.
  • Mono- or di- (C ⁇ -C 4 ) -alkylaminocarbonyl stands for an amino group linked via a carbonyl group with one or two identical or different ones straight-chain or branched alkyl substituents, each having 1 to 4 carbon atoms.
  • (d-QQ-Alkoxy stands for a straight-chain or branched AKkoxy radical with 1 to 6 carbon atoms. Examples include: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert.-butoxy, n-pentoxy and n- Hexoxy, from this
  • (d -C 6 ) alkanoyl represents a straight-chain or branched alkyl radical having 1 to 6
  • Aryl residue is linked via two positions.
  • Examples include: pyridyl, pyridyl-N-oxide, pyrimidyl, pyridazinyl, pyrazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl or isoxazolyl, indolicenyl, indolyl, benzo [b] fhienyl, benzo [b] furyl, Benzothiadiazolyl, indazolyl, quinolyl, isoquinolyl, naphthyridinyl, quinazolinyl.
  • Piperidinyl, morpholinyl and pyrrolidinyl are preferred.
  • Ring size such as 3- to 7-membered heterocycles.
  • A stands for a ring member -CH 2 -D- or -D-CH 2 -,
  • D represents -CH 2 -, -O- or -S-
  • X represents (C 2 -C 4 ) alkylene or cyclohexylene
  • R 1 represents hydrogen, (-CC 4 ) -alkyl, which is optionally substituted up to three times by fluorine, or (C 3 -C 6 ) -cycloalkyl,
  • R 2 represents a group of the formula -SO 2 -R 4 , -CO-R 7 or -CO-OR 10 ,
  • R 4 represents (C -; - C 4 ) -alkyl, which is optionally substituted up to three times by fluorine,
  • R 7 represents (C 6 -do) aryl which is optionally substituted by nitro
  • A stands for a ring member -CH 2 -D- or -D-CH 2 -,
  • R 1 represents hydrogen, (dC 4 ) -alkyl, which is optionally substituted up to three times by fluorine, or (C 3 -C 6 ) -cycloalkyl,
  • E represents (C 6 -C 10 ) aryl or a 5- to 13-membered saturated, partially unsaturated or aromatic heterocycle with up to three heteroatoms from the series N, O and / or S, the ring systems in each case optionally up to triple, identical or different, by substituents selected from the group of nitro, cyano, fluorine, chlorine, bromine, (dC ⁇ alkyl, which in turn is optionally substituted by benzamido, trifluoromethyl, (C 3 -C 6 ) cycloalkyl,
  • R and R together with the nitrogen atom to which they are bound form a saturated 5- to 10-membered, mono- or bicyclic heterocycle which has a carbonyl group in the direct vicinity of the nitrogen atom to which R 1 and R 2 are bonded , in which up to two ring carbon members are optionally replaced by oxygen and / or sulfur and which is optionally up to three times, identical or different, selected by substituents from the group of (dC) -alkyl, hydroxy, oxo, (dC 4 ) Alkoxy, carboxyl, (dC 4 ) alkoxycarbonyl and halogen is substituted,
  • R 3 represents hydrogen
  • A stands for a ring member -CH 2 -D- or -D-CH 2 -,
  • R 1 represents hydrogen, methyl, trifluoromethyl or cyclopropyl, R> 2 for a group of the formula
  • E represents (C 6 -C ⁇ o) aryl or a 5- to 10-membered partially unsaturated or aromatic heterocycle with up to three heteroatoms from the series N, O and or S, the ring systems in each case optionally up to twice, identical or different, by
  • G is absent or represents phenylene or thienylene
  • R, 3 represents hydrogen
  • the present invention also relates to a process for the preparation of the compounds of the formula (I) according to the invention, wherein
  • Y represents R 2 or a customary amino protecting group and X, R 1 and R 2 have the meaning given above,
  • Y represents R 2 or a customary amino protective group and A, X, R 1 and R 2 have the meaning given above, implements,
  • Y represents R or a customary amino protecting group and A, X, R and R have the meaning given above,
  • A, X and R 1 have the meaning given above, transferred and optionally in the presence of a base, with compounds of the formula (VII)
  • R 2 has the meaning given above and T represents a leaving group
  • R 3 has the meaning given above but is not hydrogen and T represents a leaving group
  • this aldehyde group can subsequently be converted into the corresponding oxime using the customary methods
  • Suitable solvents for the process described above are organic solvents which are inert under the reaction conditions. These include halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, 1,2-dichloroethane, trichloroethane, tetrachloroethane, 1,2-dichloroethylene or trichlorethylene, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol hydrocarbons such as benzene dimethyl ether, Xylene, toluene, hexane or cyclohexane, dimethylformamide, dimethyl sulfoxide, acetonitrile, pyridine or hexamethylphosphoric triamide. It is also possible to use solvent mixtures of the aforementioned solvents.
  • halogenated hydrocarbons such as dichloromethane, trichloromethane,
  • the reactions generally take place in a temperature range from -78 ° C. to the reflux temperature, preferably in the range from 0 ° C. to the reflux temperature.
  • the reactions can be carried out at normal, elevated or reduced pressure (e.g. in the range from 0.5 to 5 bar). Generally one works at normal pressure.
  • bases are suitable as bases.
  • bases preferably include alkali metal hydroxides such as sodium or potassium hydroxide or alkali metal carbonates such as sodium or potassium carbonate or sodium or potassium methoxide or sodium or potassium ethanolate or potassium tert-butoxide or amides such as sodium amide, lithium bis (trimethylsilyl) amide or lithium diiso- propylamide or amines such as triethylamine, diisopropylemylamine, diisopropylamine, 4-N, N-dimethylaminopyridine or pyridine.
  • alkali metal hydroxides such as sodium or potassium hydroxide or alkali metal carbonates such as sodium or potassium carbonate or sodium or potassium methoxide or sodium or potassium ethanolate or potassium tert-butoxide
  • amides such as sodium amide, lithium bis (trimethylsilyl) amide or lithium diiso- propylamide or amines such as triethylamine, diisopropylemylamine
  • the temperature range for the reaction of compounds of formula (II) with compounds of formula (LTI) to compounds of formula (IV) is in particular between 80 and 120 ° C.
  • chlorocarbonyl isocyanate is added in particular at room temperature, the further reaction then takes place in particular in a temperature range between 80 and 120 ° C.
  • the reaction of compounds of formula (VI) with compounds of formula (VII) takes place in the event that R 2 is a sulfonyl radical, in particular at room temperature.
  • reaction of compounds of the formula (II) with compounds of the formula (III) to compounds of the formula (TV) can, if appropriate, be accelerated by adding catalytic amounts of acid, preferably organic sulfonic acid, in particular camphorsulfonic acid.
  • acid preferably organic sulfonic acid, in particular camphorsulfonic acid.
  • Suitable leaving groups T for compounds of the formulas (VII) and (VIII) are: halogen, mesylate, tosylate, triflate or 1-imidazolyl, chlorine is preferred.
  • the amino protection group for compounds of the formulas (III), (TV) and (V) are the residues usually used, as described, for example, in TW Greene, PGM Wuts, Protective Groups in Organic Synthesis, second edition, New York, 1991. Examples include: benzyl or BOG (tert. Butoxycarbonyl).
  • the amino protective group is split off in the conversion of compounds of the formula (V) to compounds of the formula (VI) in the manner customary for the respective amino protective group, as described, for example, in TW Greene, PGM
  • transition metal-catalyzed coupling reaction of aryl or hetaryl bromides with organotin (Stille coupling) or organoboron compounds (Suzuki coupling) takes place under the usual reaction conditions in the presence of a catalyst, preferably in the presence of a transition metal catalyst, in particular in the presence of a palladium catalyst ( see for example J. Tsuji, Palladium Reagents and Catalysts, J. Wiley & Sons, 1995) preferably in dimethylformamide as solvent.
  • Palladium (O) or palladium ( ⁇ compounds, in particular bis (triphenylphosphine) palladium ( ⁇ ) chloride or tetrakis (triphenylphosphine) palladium (O), are preferably used as transition metal catalysts, in the case of the use of organic boron Compounds (Suzuki coupling, overview: N. Miyaura, A. Suzuki, Chem. Rev. 1995, 95, 2457-2483), the reaction takes place especially in one
  • the compounds of formula (I) according to the invention have an unforeseeable, valuable pharmacological spectrum of action and are therefore particularly suitable for the prophylaxis and / or treatment of diseases.
  • cardiovascular diseases such as e.g. unstable angina and arteriosclerosis, neuronal and neurodegenerative diseases such as Epilepsy, chronic pain, Alzheimer's disease and Parkinson's disease, traumatic brain injuries, septic shock and arthritis, diabetes, chronic colitis, sudden hearing loss, inflammatory
  • Lung diseases such as Asthma and chronic bronchitis and cancer.
  • the present invention also relates to the use of the substances of the formula (I) for the production of medicaments and pharmaceutical compositions for the prophylaxis and / or treatment of the aforementioned clinical pictures.
  • the present invention further relates to a method for the prophylaxis and / or treatment of the aforementioned clinical pictures with the substances of the formula (I).
  • the compounds according to the invention can also be used in the treatment of acute myocardial infarction in combination with one or more of the following medicaments which belong to the standard therapy for acute myocardial infarction: calcium channel blockers (such as, for example, nifedipine, diltiazem,
  • nitrovasodilators such as isosorbide dinitrate, glycerol trinitrate, Isosorbide-5-mono-nitrate, molsidomine
  • beta-blockers such as metoprolol, atenolol, propranolol, solatol
  • platelet aggregation inhibitors such as acetylsalicylic acid, triclopidine, clopidrogrel
  • thrombolytics thrombolytics (fibrinolytokinase), such as streptolytic drugs, such as strepplase, e.g.
  • Urokinase, anistreplase), anticoagulants such as heparin, warfarin, phenprocoumarin, low molecular weight heparins
  • ACE inhibitors such as enalapril
  • glycoprotein im / Tfla receptor antagonists such as tirofiban, eptifibatide
  • anti-arrhythmic agents such as Amiodarone
  • beta-adrenergic agonists such as dopamine, dobutamine
  • the inhibition of PARS activity can be expressed as a% value of PARS inhibition
  • NAD + Mix 2 mM NAD + in buffer
  • NAD + (Sigma) solutions are freshly prepared before each test. 3 ⁇ l of labeled [ 14 C] NAD + (2.8 kBq, from Amersham) are added to 7 ⁇ l of cold NAD + solution in each case.
  • TCA is stored as a 10% solution at 4 ° C.
  • Human PARS protein is expressed recombinantly in the Baculo virus system (Bac-To-Bac, Baculo virus expression system; Instruction Manual; Life Technologies) and purified. 500 ⁇ l aliquots are stored at -80 ° C.
  • the compounds to be tested are dissolved in a concentration of 10 mM in DMSO (dimethyl sulfoxide).
  • the assay is carried out in deep 96-hole plates.
  • DHCH 1,5-dihydroxyisoquinoline
  • PARS inhibitors investigated to protect cells from cell death induced by incubation with H 2 O 2 .
  • the incubation of endothelial cells with H 2 O 2 leads to the generation of DNA strand breaks, which in turn activate the PARS, which leads to a drastic decrease in energy in the cells and cell death.
  • Living cells were quantified using a fluorimetric redox indicator (Alamar blue) implemented in the electron transport system of the mitochondria.
  • MHEC5-T cells / hole (DSM ACC 336; German coUection of microorganisms and cell cultures) are determined as 4-fold determination on a 96-hole plate seeded. After 24 hours, the cells are incubated with 3 mM aqueous H 2 O 2 solution and various concentrations of the substances in the presence of 6% Alamar blue solution in the medium for 5 hours at 37 ° C. 10 ⁇ M 1,5-dihydroxyisoquinoline (DHCH) solution is used as the reference substance. After the incubation, the fluorescence is measured at 530-560 nm excitation wavelength and 590 nm emission wavelength.
  • DSM ACC 336 German coUection of microorganisms and cell cultures
  • The% value of cell protection is calculated as the difference between the living cells treated with H 2 O 2 only and the cells treated with H 2 O 2 and PARS inhibitor. 10 ⁇ M DHCH is used as the internal standard and 100% protection is set. The values obtained for the other substances were compared to this value.
  • DHCH has an EC 50 value of
  • isolated rat hearts are subjected to a 60-minute “low flow” phase to generate global ischemia and investigated the effect of the substances on the restoration of the left ventricular pressure (LVPmax) and the contraction force (dP / dt) during the reperfusion phase.
  • LVPmax left ventricular pressure
  • dP / dt contraction force
  • the present invention furthermore relates to medicaments and pharmaceutical compositions which comprise at least one compound of the formula (T), preferably together with one or more pharmacologically acceptable auxiliaries or excipients, and their use for the purposes mentioned above.
  • the active substance can act systemically and / or locally.
  • it can be applied in a suitable way, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, transdermal, conjunctival, otic or as an implant.
  • the active ingredient can be administered in suitable administration forms for these administration routes.
  • Known application forms which release the active ingredient quickly and / or modified such as e.g. Tablets (non-coated and coated tablets, e.g. enteric coatings), capsules, dragees, granules, pellets, powders, emulsions, suspensions and solutions.
  • Tablets non-coated and coated tablets, e.g. enteric coatings
  • capsules dragees, granules, pellets, powders, emulsions, suspensions and solutions.
  • Parenteral administration can be done by bypassing a resorption step (intravenously, intraarterially, intracardially, intraspinally or intralumbally) or by switching on absorption (intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally).
  • Suitable forms of application for parenteral administration include injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates and sterile powders.
  • Inhalation drug forms e.g.
  • the active compounds can be converted into the administration forms mentioned in a manner known per se. This is done using inert, non-toxic, pharmaceutically suitable excipients. These include Carriers (e.g. microcrystalline cellulose), solvents (e.g. liquid polyethylene glycols), emulsifiers
  • dispersants e.g. polyvinylpyrrolidone
  • synthetic and natural biopolymers e.g. albumin
  • stabilizers e.g. antioxidants such as ascorbic acid
  • colorants e.g. inorganic pigments such as iron oxides
  • taste and / or odor correctors e.g. sodium dodecyl sulfate
  • dispersants e.g. polyvinylpyrrolidone
  • synthetic and natural biopolymers e.g. albumin
  • stabilizers e.g. antioxidants such as ascorbic acid
  • colorants e.g. inorganic pigments such as iron oxides
  • taste and / or odor correctors e.g. sodium dodecyl sulfate
  • dispersants e.g. polyvinylpyrrolidone
  • synthetic and natural biopolymers e.g. albumin
  • stabilizers e.g. antioxidants such as ascorbic acid
  • the therapeutically active compounds should be present in the pharmaceutical preparations listed above in a concentration of about 0.1 to 99.5, preferably about 0.5 to 95% by weight of the total mixture, i.e. H. the active substance should be present in amounts sufficient to achieve the dosage range indicated.
  • the pharmaceutical preparations listed above can also contain further active pharmaceutical ingredients.
  • the active compound (s) according to the invention in total amounts of from about 0.1 to about 500, preferably from 1 to 100 mg / kg of body weight per 24 hours, optionally in the form to be administered by several individual guests to achieve the desired results.
  • a single dose contains the active ingredient (s) according to the invention preferably in amounts of about 0.1 to 80, in particular 1 to 30 mg / kg body weight.
  • the reaction mixture is distributed between ethyl acetate and saturated sodium dihydrogen phosphate solution.
  • the organic extract is washed with water and dried over sodium sulfate. Since the product is also present in the aqueous phase, the aqueous phase is evaporated to dryness and the residue obtained is stirred with methanol.
  • the methanolic extract is combined with the ethyl acetate phase, evaporated and the product is purified by column chromatography (silica gel, ethyl acetate / methanol 4: 1). The product fraction becomes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux inhibiteurs de PARP sous forme de dérivés d'amidoalkyle-uracile de formule (I), un procédé permettant de les préparer et leur utilisation comme principes actifs de médicaments pour assurer la prophylaxie et/ou le traitement de lésions dues à l'ischémie et à la reperfusion.
EP01947443A 2000-07-18 2001-07-05 Amidoalkyle-uraciles substitues utilises comme inhibiteurs de parp (poly(adp-ribose)-polymerase) Ceased EP1303497A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10034801A DE10034801A1 (de) 2000-07-18 2000-07-18 Substituierte Amidoalkyl-uracile und ihre Verwendung
DE10034801 2000-07-18
PCT/EP2001/007670 WO2002006247A1 (fr) 2000-07-18 2001-07-05 Amidoalkyle-uraciles substitues utilises comme inhibiteurs de parp (poly(adp-ribose)-polymerase)

Publications (1)

Publication Number Publication Date
EP1303497A1 true EP1303497A1 (fr) 2003-04-23

Family

ID=7649257

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01947443A Ceased EP1303497A1 (fr) 2000-07-18 2001-07-05 Amidoalkyle-uraciles substitues utilises comme inhibiteurs de parp (poly(adp-ribose)-polymerase)

Country Status (6)

Country Link
US (1) US6649618B2 (fr)
EP (1) EP1303497A1 (fr)
AU (1) AU2001269121A1 (fr)
CA (1) CA2416036A1 (fr)
DE (1) DE10034801A1 (fr)
WO (1) WO2002006247A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10201240A1 (de) * 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
US7009052B2 (en) * 2003-03-20 2006-03-07 Warner Lambert Company Llc Sulfonamide derivatives
EP2409700A1 (fr) 2007-05-08 2012-01-25 Schering Corporation Procédés pour le traitement de formulations intraveineuses comprenant du témozolomide
CN104066723B (zh) * 2011-11-01 2016-06-29 南京英派药业有限公司 1-(芳基甲基)-5,6,7,8-四氢喹唑啉-2,4-二酮和相关化合物及其应用
EP3332645A1 (fr) 2016-12-12 2018-06-13 Bayer Cropscience AG Utilisation de pyrimidinedione ou ses sels respectifs en tant qu'agent contre l'agression abiotique des plantes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1959705A1 (de) 1969-11-28 1971-06-03 Bayer Ag Verfahren zur Herstellung von Uracilderivaten
DE2126148A1 (en) 1971-05-26 1972-12-07 Farbenfabriken Bayer Ag, 5090 Leverkusen Prepn of uracil derivs - useful as plant - protection agents and their inters
DE2142317A1 (de) 1971-08-24 1973-03-01 Bayer Ag Hypnotisches mittel
JP2860689B2 (ja) * 1990-03-14 1999-02-24 第一製薬株式会社 ピリミジン誘導体
JP3264579B2 (ja) 1994-03-18 2002-03-11 扶桑薬品工業株式会社 クラミジア・トラコマチス血清型の鑑別法
GB9702701D0 (en) * 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
EP1142881A4 (fr) 1999-01-14 2003-05-07 Meiji Seika Kaisha Inhibiteurs de poly(adp-ribose) polymerase consistant en des derives de pyrimidine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0206247A1 *

Also Published As

Publication number Publication date
US20030022905A1 (en) 2003-01-30
WO2002006247A1 (fr) 2002-01-24
WO2002006247A8 (fr) 2002-02-21
DE10034801A1 (de) 2002-01-31
AU2001269121A1 (en) 2002-01-30
CA2416036A1 (fr) 2002-01-24
US6649618B2 (en) 2003-11-18

Similar Documents

Publication Publication Date Title
EP1622880B3 (fr) Dihydroquinazolines substituees a proprietes antivirales
EP1425283B1 (fr) Nouvelles 4-aminofuropyrimidines et leur utilisation
DE10312969A1 (de) Benzofuro-1,4-diazepin-2-on-Derivate
EP1572642A1 (fr) Derives d'uree 3-pyrrolyle et leur utilisation en tant qu'agents antiviraux
DE10343098A1 (de) Tetrahydrochinoxaline und ihre Verwendung
EP1467975A1 (fr) Alkyles uraciles substitues et leur utilisation
EP1625129B1 (fr) Dihydroquinazolines substituees par heterocyclyle et leur utilisation comme antiviraux
EP1303497A1 (fr) Amidoalkyle-uraciles substitues utilises comme inhibiteurs de parp (poly(adp-ribose)-polymerase)
EP1685123B1 (fr) Dihydroquinazolines ii substituees
EP1339699A1 (fr) Amidoalkyl-uraciles substitues et leur utilisation
DE102004022672A1 (de) Substituierte Azachinazoline
DE10305785A1 (de) Dihydrochinazoline
EP1562913A1 (fr) Quinazolines substituees utilisees comme agents antiviraux, en particulier contre des cytomegalovirus
EP1476164B1 (fr) Quinoxalinones et leur utilisation notamment pour traiter des affections cardiovasculaires
EP1732901B1 (fr) Composes imidazole a substitution 4-aminocarbonylamino a activite antivirale
WO2004058716A1 (fr) 4-aryl-pyridines servant d'antagonistes de kiss-1
DE10203086A1 (de) 5-Ring Heterozyklen
EP1499603A1 (fr) Lactones-urees antivirales

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030218

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20030826

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER HEALTHCARE AG

RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT

APAX Date of receipt of notice of appeal deleted

Free format text: ORIGINAL CODE: EPIDOSDNOA2E

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20080112